menu
    • menu

    Company profile for Tune Therapeutics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Tune Therapeutics is pioneering epigenomic therapies to treat complex diseases by targeting gene expression rather than altering the DNA itself. Their TEMPO platform allows for precise modulation of gene activity, offering a way to treat diseases like cancer, genetic conditions, and aging. This approach could revolutionize regenerative medicine by providing a non-invasive method to treat a wide range of chronic diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tune TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    300 Morris St, Suite 320, Durham, NC 27701
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://tunetx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tunetx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novotech Wins Citeline CRO Partnership of the Year Award
    Novotech Wins Citeline CRO Partnership of the Year Award

    13 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250513574699/en/Novotech-Wins-Citeline-CRO-Partnership-of-the-Year-Award-for-Strategic-Collaboration-with-Tune-Therapeutics

    BUSINESSWIRE
    13 May 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Tune Tx's $175M Series B to Fund Epigenetic HBV Therapy's Trials

    Details:

    The financing will accelerate the development of the company’s existing pipeline, currently anchored by Tune-401 – its clinical-stage epigenetic silencing drug for chronic Hepatitis B.


    Lead Product(s): Tune-401

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Oligonucleotide

    Sponsor: New Enterprise Associates

    Deal Size: $175.0 million Upfront Cash: Undisclosed

    Deal Type: Series B Financing January 13, 2025

    blank

    01

    Tune Therapeutics

    U.S.A
    arrow
    AMWC Asia-TDAC
    Not Confirmed

    Tune Therapeutics

    U.S.A
    arrow
    AMWC Asia-TDAC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tune-401

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : New Enterprise Associates

    Deal Size : $175.0 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    Tune Tx's $175M Series B to Fund Epigenetic HBV Therapy's Trials

    Details : The financing will accelerate the development of the company’s existing pipeline, currently anchored by Tune-401 – its clinical-stage epigenetic silencing drug for chronic Hepatitis B.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Undisclosed

    January 13, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B

    Details:

    Tune-401 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis B, Chronic.


    Lead Product(s): Tune-401

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 04, 2024

    blank

    02

    Tune Therapeutics

    U.S.A
    arrow
    AMWC Asia-TDAC
    Not Confirmed

    Tune Therapeutics

    U.S.A
    arrow
    AMWC Asia-TDAC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tune-401

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatiti...

    Details : Tune-401 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis B, Chronic.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    November 04, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search